Forward Pharma

Forward Pharma. It is a biopharmaceutical company headquartered in Copenhagen, Denmark, focused on the development of proprietary formulations of dimethyl fumarate for the treatment of autoimmune diseases and other inflammatory conditions. The company's primary asset is FP187, a delayed-release formulation intended for once-daily dosing. Its corporate history is deeply intertwined with significant intellectual property litigation, particularly concerning the blockbuster multiple sclerosis therapy Tecfidera.

History

The company was incorporated in 2005 by a group of scientists and entrepreneurs, including Florian Schönharting, with initial operations based in Switzerland. Early research efforts concentrated on optimizing fumaric acid ester therapies, leading to the development of its lead candidate. In 2012, it completed a reverse merger with a publicly traded shell company, thereby gaining a listing on the NASDAQ stock exchange under the ticker symbol FWP. A pivotal moment in its trajectory occurred in 2017 when it entered into a landmark settlement and license agreement with Biogen Inc. and Biogen Idec International Neuroscience GmbH, resolving protracted global patent disputes. This agreement resulted in a substantial one-time payment and entitled it to royalties on certain sales of Tecfidera until 2021, fundamentally shaping its financial strategy and operational focus.

Intellectual property and legal disputes

Its intellectual property portfolio is centered on U.S. Patent No. 8,399,514, which covers certain methods of treating multiple sclerosis with specific doses of dimethyl fumarate. The company engaged in a protracted interference proceeding before the U.S. Patent and Trademark Office against Biogen Inc. concerning the invention date of this technology. The high-stakes legal battle, which also involved parallel proceedings in the European Patent Office, was ultimately settled in 2017. Under the terms of the global agreement, it granted Biogen a license to its intellectual property, and in return, received a $1.25 billion payment. It also retained certain rights to develop FP187 for all indications except multiple sclerosis in the United States and most other countries, a key restriction defining its subsequent research scope.

Corporate affairs and financials

Following the 2017 settlement with Biogen, its business model shifted from active drug development to an asset management and capital allocation focus. The substantial cash infusion from the agreement led to a significant special dividend distribution to shareholders and a major share repurchase program. Its financial performance has since been largely defined by investment income and ongoing administrative expenses, as it maintains a minimal operational footprint. The company's stock has been subject to volatility often tied to announcements regarding the Biogen agreement, litigation outcomes, and strategic reviews. Corporate governance is overseen by a board of directors, with significant shareholding by entities including Kyle Bass's Hayman Capital Management.

Scientific research and development

Its core research has historically focused on FP187, a proprietary, delayed-release formulation of dimethyl fumarate. The compound is a member of the fumaric acid ester class, which is believed to exert therapeutic effects through activation of the Nrf2 pathway, modulating the immune system and providing cytoprotection against oxidative stress. Preclinical and early clinical studies investigated its potential in conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. However, clinical development was substantially curtailed following the 2017 license agreement with Biogen, which restricted its pursuit of multiple sclerosis programs. Subsequent research activities have been minimal, with resources primarily directed toward protecting its remaining intellectual property estate rather than active clinical trials.

Key personnel and leadership

Leadership has been characterized by stability in the post-settlement era. Claus Bo Svendsen has served as Chief Executive Officer since 2016, bringing experience from previous roles at Novo Nordisk and Bavarian Nordic. The Chairman of the board is co-founder Florian Schönharting, a principal architect of the company's early intellectual property strategy. Other notable board members have included James G. Cullen, former president of Johnson & Johnson's Ethicon Endo-Surgery division, and Göran Ando, former chairman of the board for Novo Nordisk. The executive team and board possess extensive backgrounds in pharmaceutical licensing, corporate finance, and biotechnology venture creation, aligning with the company's strategic direction following its pivotal legal resolution.

Category:Biotechnology companies of Denmark Category:Pharmaceutical companies established in 2005 Category:Companies listed on NASDAQ